Nile Therapeutics (NLTX) Completes Dosing in CD-NP Phase II

Nile Therapeutics, Inc. (Nasdaq: NLTX) today announced that it has completed the dosing of the last patient in NIL-CDNP-CT005, an open-label, single-blind, placebo-controlled Phase II study of CD-NP in patients with acute decompensated heart failure, or ADHF. The study was designed to provide additional information on the safety and tolerability...

Read More